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Edited by Judit OvadiAbstract The lytic transglycosylases cleave the bacterial cell
wall heteropolymer peptidoglycan with the same speciﬁcity as
the muramidases (lysozymes), between the N-acetylmuramic
acid and N-acetylglucosamine residues, with the concomitant
formation of a 1,6-anhydromuramoyl residue. The putative
catalytic residue in the family 3 lytic transglycosylase from
Pseudomonas aeruginosa, Glu162 as identiﬁed by sequence
alignment to the homologous enzyme from Escherichia coli, was
replaced with both Ala and Asp by site-directed mutagenesis.
Neither mutant enzyme diﬀered structurally from the wild-type
enzyme, as judged by CD spectroscopy, but both were enzymat-
ically inactive conﬁrming the essential role of Glu162 in the
mechanism of action of this lytic transglycosylase. The b-
hexosaminidase inhibitor NAG-thiazoline was shown to inhibit
the activity of lytic transglycosylase activity, thus providing the
ﬁrst direct evidence that the formation of the 1,6-anhydromura-
moyl residue may proceed through an oxazolinium ion interme-
diate involving anchimeric assistance. Using surface plasmon
resonance and diﬀerence absorbance spectroscopy, Kd values of
1.8 and 1.4 mM, respectively, were determined for NAG
thiazoline, while its parent compound N-acetylglucosamine
neither inhibited nor appeared to bind the lytic transglycosylase
with any signiﬁcant aﬃnity.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Lytic transglycosylases (LTs), a class of bacterial autolysins,
function to cleave peptidoglycan at the same site as lysozymes
(EC 3.2.1.17; peptidoglycan N-acetylmuramoyl hydrolase),* Corresponding author. Fax: +1-519-837-1802.
E-mail address: aclarke@uoguelph.ca (A.J. Clarke).
1 Present address: Dade Behring Inc., 700 GBC Drive, Newark, DE
19714, USA.
Abbreviations: AnhMurNAc, 1,6-anhydro-N-acetylmuramic acid; Glc-
NAc, N-acetylglucosamine; HPAEC, high pH anion-exchange
chromatography; IPTG, isopropyl-b-D-thiogalactoside; LT, lytic
transglycosylase; Mlt, membrane-bound lytic transglycosylase; Mur-
NAc, N-acetylmuramic acid; NAG-thiazoline, N-acetylglucosamine
thiazoline; sMlt, soluble derivative of membrane-bound lytic transgly-
cosylase
0014-5793/$22.00  2004 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2004.08.006speciﬁcally the b-(1! 4)-glycosidic bond between N-acetyl-
muramic acid (MurNAc) and N-acetylglucosamine (GlcNAc)
residues. However, LTs are catalytically distinct from the hy-
drolytic lysozymes because they cleave peptidoglycan with the
concomitant formation of 1,6-anhydro-MurNAc (AnhMur-
NAc) residues [1]. These enzymes contribute to the metabolism
of peptidoglycan but their exact role has not been determined.
They have been implicated as space makers for the insertion of
new peptidoglycan into the cell wall during peptidoglycan re-
modeling and cell growth and as cell wall ‘zippers’ during cell
division [2,3]. They may also function in the recycling of old
wall material and macromolecular transport systems of Gram-
negative bacteria [recently reviewed in 4].
LTs appear to be ubiquitous in the eubacteria that produce
peptidoglycan (viz., all but the cell wall-less mycoplasmas) and
even in some lytic bacteriophages [5]. The Gram-negative,
human opportunistic pathogen Pseudomonas aeruginosa pro-
duces four family 3 LTs [5]. The genes encoding all four have
been cloned and expressed in Escherichia coli [6,7]. One of
these, MltB, shares 66% amino acid identity with the E. coli
enzyme and both have been demonstrated to be lipoproteins
[6,8,9]. All four family 3 enzymes from P. aeruginosa contain
an invariant glutamyl residue which comprises one of the
family’s consensus sequences [5] and has been identiﬁed as the
putative catalytic acid/base in E. coli MltB [11].
Determination of the crystal structure of a naturally pro-
duced, soluble derivative of the family 3 E. coli membrane-
bound LT B (MltB; Slt35) complexed with GlcNAc [10],
GlcNAc-MurNAc-L-Ala-D-Glu, and the inhibitor bulgecin
[11] by Dijkstra and his colleagues led to the identiﬁcation of
four sugar-binding subsites within the enzyme with the in-
variant Glu162 poised between the )1 and +1 binding site. No
other potential catalytic residue was observed in close prox-
imity to this catalytic center. A similar situation was also
found with the complex formed between Slt70, a family 1 LT
from E. coli, and either a 1,6-anhydromuropeptide [12] or
bulgecin [13]. The presence of a single catalytic residue at the
active center of LTs indicates that these enzymes appear to use
a diﬀerent mechanism of action compared to most glycosid-
ases, including lysozyme, which employ a catalytic diad of
acidic residues [14]. In the double-displacement reaction
mechanism of hen egg-white lysozyme, Glu35 remains pro-
tonated at physiological pH to act as a catalytic acid, while
deprotonated Asp52 serves as a nucleophile to stabilize the
putative oxocarbenium transition state formed during hydro-
lysis resulting in a covalent intermediate [15]. With the LTs, theation of European Biochemical Societies.
Fig. 1. Structures of NAG-thiazoline (1) and the proposed reaction
intermediate of LTs, muramoyl oxazoline (2).
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others to investigate whether these enzymes behave like the
glycosyl hydrolase family (CAZy) 18 chitinases and chitobi-
ases, family 20 N-acetyl-b-hexosaminidases, and the family 23
goose-type lysozymes. Each of these glycosidases was found to
lack a carboxylate suitably positioned to stabilize the ox-
ocarbenium ion transition state [16–20] and based on kinetic
and X-ray crystallographic analyses of enzyme–inhibitor in-
teractions together with theoretical considerations, hydrolysis
has been proposed to involve a substrate-assisted mechanism
and an oxazoline intermediate [18,21–29].
Recently, we have shown that the b-hexosaminidase inhibi-
tor N-acetylglucosamine thiazoline (NAG-thiazoline) [23,30]
(Fig. 1) causes morphological changes to E. coli when added
alone to growing cultures, suggesting that the peptidoglycan
biosynthetic complexes of LTs and penicillin-binding proteins
are aﬀected [31]. Furthermore, NAG-thiazoline protects the
cells from penicillin-induced lysis, a process requiring autoly-
sins including the LTs. In this study, we conﬁrm the identiﬁ-
cation of Glu162 as an essential catalytic residue and we show
that NAG-thiazoline inhibits the enzymatic activity of an en-
gineered soluble derivative of P. aeruginosa MltB (sMltB).2. Materials and methods
2.1. Chemical reagents and enzymes
Deoxynucleoside triphosphate set, PCR grade, ExpandTM long
template PCR system, FastStart Taq DNA polymerase, glycine, iso-
propyl-b-D-thiogalactoside (IPTG), and Pwo polymerase were from
Roche Molecular Biochemicals (Laval, PQ), while BCA protein assay
kit was from Pierce (Rockford, IL). All other chemicals were supplied
by either Sigma Chemical Co. (St. Louis, MO) or Fisher Scientiﬁc
(Nepean, Ont.) and were of reagent grade or HPLC-grade where ap-
propriate.Table 1
Bacterial strains and plasmids used in this study
Strain or plasmid Genotype or relevant characteristic
E. coli strains
DH5a K-12 / 80d lacZ_M15 endA1 hsdR17 (rK
GyrA96 relA1 q(lacZYA-argF) U169 F
BL21[kDE3] pLysS F ompT hsdSB(rBm

B ) gla dcm met (DE3
Plasmids
pET30a(+) IPTG inducible expression vector; KmR
pNBAC54-1 pET30a(+) derivative containing mltB on
encoding an N-terminal truncation of Ar
pNBAC-ME162A PNBAC54-1 derivative containing the site
Glu162!Ala
pNBAC-ME162D PNBAC54-1 derivative containing the site
Glu162!AspNAG-thiazoline (Fig. 1) was prepared from peracetylated glucosa-
mine using Lawesson’s reagent as previously described [31]. For inhi-
bition and binding studies, NAG-thiazoline concentrations were
corrected to reﬂect the purity of the sample as determined by NMR
using a Bruker Avance 400 and CD3OD (referenced at 4.87 ppm and
3.30 ppm for 1H and 49.15 ppm for 13C) as solvent.2.2. Bacterial strains, plasmids, and growth conditions
The bacterial strains and plasmids used and created in this study are
summarized in Table 1. Cultures were routinely grown in Luria–Ber-
tani (LB; 1% tryptone peptone, 1% NaCl, and 0.5% yeast extract)
broth or LB-agar plates at 37 C. For protein expression experiments,
cells were grown in Super Broth (3.2% tryptone peptone, 0.5% NaCl,
and 2% yeast extract) at both 18 and 37 C as appropriate. When
necessary, growth media were supplemented with antibiotics at the
following concentrations: ampicillin (Ap; 100 lg/ml), kanamycin (Km;
30 lg/ml), or chloramphenicol (Cam; 34 lg/ml).
2.3. Isolation and puriﬁcation of sMltB and its derivatives
The production, isolation, and puriﬁcation to homogeneity of a
soluble derivative of P. aeruginosa MltB (sMltB) from freshly trans-
formed E. coli with pNBAC 54-1 (encoding His6-tagged sMltB) were
conducted as previously described [6].
2.4. Site-directed mutagenesis
The QuikChangeTM site-directed mutagenesis system (Stratagene,
LaJolla, CA) was used to create single amino acid replacements within
sMltB. Conditions for the mutagenesis PCR were those suggested by
the manufacturer using PfuTurbo DNA polymerase. Plasmid
pNBAC54-1 was used as template in a PCR using the following
primers:
Glu162!Ala, 50-GGCATCATCGGCGTGGCCACCCGCTGGG-
GGCGTG-30 and 50-CACGCCCCCAGCGGGTGGCCACGCCGA-
TGATGCC-30; Glu162!Asp, 50-GGCATCATCGGCGTGGATAC-
CCGCTGGGGGCGTG-30 and 50-CACGCCCCCAGCGGGTATC-
CACGCCGATGATGCC-30, with the changed nucleotides denoted by
bold and underlined type. After PCR, the wild-type plasmid was di-
gested with DpnI (speciﬁc for methylated DNA) leaving only mutated
plasmid DNA. The DpnI-digested material was transformed into com-
petentE. coliDH5b cells andplatedonLBagar containing 30lg/mlKm.
Plasmids pNBAC-ME162A and pNBAC-ME162D encoding the
Glu162!Ala and Glu162!Asp mutants of sMltB, respectively, were
isolated from several resulting colonies and sequenced to ensure that
only the desired mutation had been made.
2.5. Expression and puriﬁcation of sMltB mutants
Escherichia coli BL21-kDE3 was freshly transformed with pNBAC-
ME162A and pNBAC-ME162D and used to inoculate cultures of
Super Broth supplemented with appropriate antibiotics. The inocu-
lated cultures were incubated at 37 C until early exponential phase
(OD600 approximately 0.5). The cultures were then cooled to 18 C for
15 min prior to the addition of IPTG (freshly prepared in water and
ﬁlter sterilized) to a ﬁnal concentration of between 0.05 and 0.1 mM.
Induced cultures were incubated for up to 18 h at temperatures ranging
from 18 to 37 C. After incubation, the cells were collected by cen-Reference or source
mK ) supE44 thi-1 Clonetech
) pLysS (CmR) Novagen
Novagen
a NdeI/XhoI fragment [13]
g-2 to Cys-17; KanR
-speciﬁc change encoding This work
-speciﬁc change encoding This work
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sonication as previously described [6].
2.6. Assay for LT activity and inhibition
The peptidoglycan substrate was isolated and puriﬁed from cultures
of P. aeruginosa PAO1 grown for 8 h at 37 C in LB broth as previ-
ously described [32]. The isolated peptidoglycan was treated with
DNase, RNase, and Pronase and re-isolated by centrifugation as de-
scribed by Glauner [33]. Assays of cleavage reactions based on the
release of soluble muropeptides from insoluble peptidoglycan sus-
pended in 50 mM ammonium acetate buﬀer, pH 5.8, were conducted
as previously described by Blackburn and Clarke [34]. For inhibition
studies, the data were plotted as percent residual activity based on the
control reaction conducted in the absence of NAG-thiazoline.
The zymography protocol employed in this study was similar to that
described by Watt and Clarke [35] and Bernadsky et al. [36] using
puriﬁed peptidoglycan incorporated into 0.75 mm thick 12.5% poly-
acrylamide gels to a ﬁnal concentration of 0.1%.
2.7. Determination of Kd for NAG-thiazoline
The binding of ligands to sMltB was determined by both surface
plasmon resonance (SPR) and diﬀerence absorption spectroscopy.
SPR experiments was performed using a BIAcore 2000 instrument
(BIAcore, Inc., NJ) and the buﬀer conditions described by Vollmer
et al. [37]. Puriﬁed sMltB in 10 mM sodium acetate buﬀer, pH 5.5, was
immobilized onto the surface of a BIAcore CM5 sensor chip via free
amino groups, and remaining binding sites were blocked by the in-
jection of 1 M ethanolamine. Control lanes on the same sensor chip
were similarly treated but for the omission of protein. Varying con-
centrations of analytes (GlcNAc or NAG-thiazoline) were passed over
the surface of the control and sMltB-His6 -coupled lanes at a ﬂow rate
of 30 ll/min. The dissociation constants (Kd) were calculated from
sensograms with the aid of BIAevaluation, version 3.1.
Absorbance spectra of puriﬁed sMltB (2.16 lM) in 10 mM am-
monium acetate buﬀer, pH 6.5, containing 100 mM NaCl were
collected using a Beckman DU-70 spectrophotometer (Beckman
Coulter Canada Inc., Mississauga, Ont.). Quantitative binding ex-
periments were performed by collecting scans of sMltB after the
sequential addition of NAG-thiazoline and incubation for 90 s at
room temperature. Each scan was corrected for dilution by multi-
plying with a correction factor [ðP Vt þ ViÞ=Vi , where Vt is the ti-
tration volume and Vi is the initial volume]. Scans were normalized
by subtraction of the scans of both ligands in the absence of enzyme
at zero ligand concentration [38]. The troughs to peak heights at
DA277–DA244 nm were plotted versus the total ligand concentration,
and dissociation constant Kd was derived by plotting DA versus DA/
[NAG-thiazoline].
Other analytical methods. Sodium dodecyl sulfate (SDS)–polyacryl-
amide gels were prepared using the discontinuous buﬀer system of
Laemmli [39] and sample buﬀer containing SDS and 2-mercap-
toethanol. Gels were stained with Coomassie Brilliant Blue R-250 as
described by Bollag et al. [40]. Protein concentrations were measured
using the Pierce BCA protein assay kit with BSA serving as the stan-
dard. Far-UV CD spectra were measured using a JASCO 600 Spec-
tropolarimeter (Japan Spectroscopic Co., Tokyo, Japan) and
estimation of secondary structure content from CD proﬁles was made
using the JASCO 600 software. Amino acid and amino sugar analysis
were performed on a Beckman System Gold amino acid analyzer as
previously described [6,32,34].Fig. 2. CD spectra of sMltB derivatives. Far-UV CD measurements
were made with puriﬁed wild-type (solid line) and Glu162!Ala (da-
shed line) sMltB at room temperature in a nitrogen gas atmosphere.
Enzymes were diluted to approximately 200 lg/ml in 50 mM acetate
buﬀer, pH 5.8, containing 0.1% Triton X-100 and scanned four times
from 190 to 250 nm. The CD measurements of the buﬀer alone have
been subtracted from the data presented.3. Results and discussion
3.1. Replacement of the catalytic acid of sMltB
Studies were initiated with sMltB, a family 3 LT [5], to
evaluate the eﬀect on activity of changing the invariant and
putative catalytic residue, Glu162, equivalent to Glu162 in E.
coli. The QuikChange mutagenesis system was used to intro-
duce changes in cloned mltB [6] and the desired mutations were
conﬁrmed by the complete nucleic acid sequencing of the
mutated genes. After testing a variety of induction tempera-
tures and IPTG concentrations to minimize the formation ofinclusion bodies, optimal expression of the sMltB derivatives
in freshly transformed E. coli BL21-k DE3 was achieved with
0.1 mM IPTG at 18 C. Cells were harvested after 3 h incu-
bation and proteins were released by sonic disruption. The
isolation of the sMltB mutants was facilitated by the presence
of C-terminal His-tags. Following the aﬃnity chromatography
on Ni2þ–NTA agarose, the isolated proteins were puriﬁed to
apparent homogeneity by a combination of cation-exchange
chromatography on Mono S and gel permeation chromatog-
raphy on Superdex-75. This protocol routinely resulted in the
preparation of 0.3–0.5 mg puriﬁed protein per liter of cell
culture.
Far-UV circular dichroism spectroscopy was used to eval-
uate and compare the secondary structures of sMltB, and the
generated mutants. Representative CD spectra of the wild-type
and Glu162!Ala mutant of sMltB are presented in Fig. 2 The
shapes of the CD spectra were identical for all proteins tested
and showed strong signals around 197, 209 and 222 nm, typ-
ical of predominantly b-helical proteins. Estimation of sec-
ondary structure content from the CD proﬁles was made using
the JASCO 600 software and it is summarized in Table 2. The
CD estimates of secondary structure for sMltB are similar to
values for E. coli Slt35 as determined directly by X-ray crys-
tallography [10,11]. Thus, in addition to sharing 72% sequence
identity, it appears likely that these two family 3 lytic trans-
glycosylases have very similar three-dimensional structures.
Additionally, these data indicate that site-speciﬁc replacement
Table 2
Secondary structure estimation of P. aeruginosa sMltB by CD spec-
troscopy and comparison to E. coli Slt35
Enzyme a-Helical b-Sheet b-Turn Random coil
SMltB w.t. 53.8 6.7 19.1 20.5
E162A 55.2 7.7 16.4 20.6
E162D 53.0 8.8 16.4 21.8
Slt35a 48.1 8.4 12.7 30.7
a Secondary structure content determined from X-ray crystallographic
structures [14,15].
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changes in the secondary structures of the sMltB derivatives.
3.2. Activity of sMltB and mutant proteins
The activity of sMltB and its mutant derivatives was eval-
uated by three methods, zymography, examining the proﬁles of
produced soluble muropeptides by high pH anion-exchange
chromatography (HPAEC)-PAD, and using the previously
established kinetic assay for LTs [6]. Representative results for
both of the former two analyses are presented in Fig. 3. The
wild-type enzyme was shown to be catalytically active by zy-
mography as demonstrated by the zone of clearing in the
stained peptidoglycan-containing zymogram gel (Fig. 3, inset).
Incubation of the enzyme with insoluble peptidoglycan sub-
strate and analysis of the soluble reaction products by HPAEC
yielded the same proﬁle of soluble muropeptide components as
previously observed [6]. Thus, three major muropeptides wereFig. 3. Eﬀect on activity of a site-directed replacement of Glu162 to
Ala or Asp in sMltB. The soluble products released from insolu-
ble peptidoglycan by (a) wild-type, (b) Glu162!Ala, and (c)
Glu162!Asp sMltB were analyzed by HPAEC and zymography. The
solid bar denotes a PAD response of 0.25 lC, and the asterisks identify
the three major muropeptides released with retention times of 51, 55,
and 62 min. Insets: Zymogram analysis. Lane 1, zymogram; lane 2,
corresponding protein sample stained with Coomassie Brilliant Blue.
The arrow denotes the zone of clearing in the zymogram of wild-type
sMltB.detected, which can be identiﬁed as anhydrodisaccharide-
tetrapeptide, anhydrodisaccharide-tripeptide, and cross-linked
anhydrodisaccharide-tetrapeptide-anhydrodisaccharide-tri-
peptide based on their retention times of 51, 55, and 62 min,
respectively, on the Dionex CarboPac PA1 anion-exchange
column and previously assigned molecular masses [6].
Using the kinetic assay, the speciﬁc activity and kcat of
the wild-type sMltB were determined to be 535
nmol min1 mg1 and 0.45 s1, respectively. In contrast, the
mutant Glu162!Ala sMltB was completely devoid of lytic
activity against peptidoglycan as judged using each of the
assays under the experimental techniques employed. This
lack of apparent activity provides strong evidence to con-
ﬁrm the identiﬁcation of Glu162 as an essential amino acid
residue, which presumably serves as the catalytic acid/base.
These data are consistent with previous ﬁndings involving
E. coli Slt70 and Slt35 in which the respective single puta-
tive catalytic glutamyl residues were replaced [10,41]. In-
terestingly, shortening the length of the glutamyl side chain
by a methyl group in P. aeruginosa sMltB had the same
eﬀect as removing the functional carboxylic acid altogether
as the Glu162!Asp sMltB was also completely inactive
(Fig. 3).
3.3. Inhibition of sMltB by NAG-thiazoline
The apparent absence of a second potential catalytic residue
in LTs proximal to the glycosidic oxygen of the scissile bond in
the peptidoglycan substrate has led to the suggestion [6,11,13]
that the mechanism of action of these enzymes may follow that
of some N-acetylglucosaminidases and chitinases [18,21–29].
The latter enzymes are thought to hydrolyze N-acetylglucos-
aminyl polymers by invoking substrate-assisted catalysis in-
volving the N-acetyl group of the aminosugar substrate at
subsite )1. Evidence in support of this hypothesis has been
provided, in part, by using NAG-thiazoline in both inhibition
and crystallographic studies of a bacterial hexosaminidase
[23,27,30]. Hence, NAG-thiazoline was synthesized in 46%
overall yield from GlcNAc by treatment with Lawesson’s re-
agent and evaluated as an inhibitor of sMltB. A 61% decrease
in apparent activity was observed for sMltB when assayed inFig. 4. Inhibition of sMltB by NAG-thiazoline. sMltB in 50 mM so-
dium acetate, pH 5.8, was treated with 0–80 mM ðdÞ NAG-thiazoline
or ðjÞ GlcNAc and then assayed for residual activity by monitoring
the release of soluble fragments from an insoluble peptidoglycan
substrate. Representative data are presented as a percentage of residual
activity in the absence of ligand.
Fig. 6. UV diﬀerence absorbance spectra of sMltB complexed with
ligands NAG-thiazoline or N-acetyl glucosamine. Representative ab-
sorbance diﬀerence spectra were obtained after incubating sMltB (2.16
lM) in 10 mM ammonium acetate buﬀer, pH 6.5 containing 100 mM
NaCl for 90 s with (a) 2.19 mM NAG-thiazoline, and (b) 2.18 mM
GlcNAc. The scans were normalized by subtraction of the scan at zero
ligand concentration. Inset: Determination of the Kd value of sMltB
for NAG-thiazoline (n ¼ 3).
C.W. Reid et al. / FEBS Letters 574 (2004) 73–79 77the presence of 60 mM NAG thiazoline (Fig. 4). As expected,
this inhibition was found to be reversible as enzymatic activity
was recovered upon dilution of the compound from the en-
zyme. In contrast, GlcNAc, the parent compound of NAG-
thiazoline, at concentrations up to 75 mM under similar con-
ditions had no apparent eﬀect on enzyme activity. Given the
inherent heterogeneity of the insoluble peptidoglycan sub-
strate, the complexity of the assay for sMltB, and the possi-
bility that the small ligand interacts with the insoluble
heteropolymeric substrate (which may account for the rela-
tively poor inhibition observed), the determination of a Ki for
the inhibition was not attempted. Instead, the binding con-
stants for the interaction of sMltB with NAG-thiazoline were
determined as described below.
3.4. Determination of Kd for NAG-thiazoline
Using a BIAcore CM5 sensor chip bound with sMltB, a
dose-dependent interaction with NAG-thiazoline was observed
(Fig. 5). In contrast, injection of up to 200 lM GlcNAc to the
same sensor chip did not generate a similar dose-dependent
response (Fig. 5 inset). Analysis of the sensograms provided a
Kd value of 1.77 0.13 mM for NAG-thiazoline. This value is
in close agreement with the Kd value obtained by diﬀerence UV
absorbance spectroscopy. Diﬀerence spectra showed a negative
trough at 277 nm with a red shift upon binding of NAG-
thiazoline to the protein (Fig. 6). This red shift indicates a
conformational change of an aromatic residue to a more non-
polar environment. Saturation curves of sMltB titrated with
NAG-thiazoline and transformation of the data (Fig. 6, inset)
gave a Kd of 1.36 0.077 mM. Again, in contrast, addition of
GlcNAc showed a small positive peak at 277 nm which can be
attributed to either non-speciﬁc binding to the protein or
binding to another subsite of the enzyme’s substrate binding
cleft. These data thus provide further evidence for the speci-
ﬁcity of binding that the thiazoline moiety confers.
3.5. Concluding remarks
Dijkstra and co-workers [11] have proposed that the puta-
tive oxocarbenium ion transition state formed during the
cleavage of peptidoglycan by LTs is stabilized by the N-acetyl
oxygen of MurNAc at subsite )1 either by a charge–chargeFig. 5. SPR sensogram of molecular interactions between sMltB and
NAG-thiazoline. The sensograms show the interaction for 60 s of three
concentrations of NAG-thiazoline (a, 20; b, 100; and c, 200 lM) with
sMltB immobilized onto a CM5 sensor chip using a BIAcore 2000.
Inset: SPR sensogram obtained by a single injection of 200 lM Glc-
NAc to the same sensor chip.interaction or by the formation of a covalent oxazolinium in-
termediate. Given our current observations with NAG-thiaz-
oline, it is tempting to suggest that we have provided the ﬁrst
evidence for the latter mechanism involving an oxazolinium
ion intermediate. Thus, the catalytic glutamyl residue (Glu162)
is proposed to serve as an acid catalyst to donate a proton to
the glycosidic oxygen of the linkage to be cleaved leading to
the formation of an intermediate with oxacarbenium ion
character (Fig. 7). In the absence of an anion/nucleophile in
close proximity to stabilize this oxacarbenium intermediate,
the LTs would employ anchimeric assistance of the MurNAc
2-acetamido group resulting in the formation of an oxazolin-
ium ion intermediate. With the shielding of the intermediate
from solvent water [11], this would then be followed by ab-
straction of the C-6 hydroxyl proton of the oxazolinium spe-
cies involving the same catalytic glutamyl residue which now
serves as the base catalyst leading to the formation of 1,6-
anhydromuramic acid product.
Mechanism-based inhibitors are expected to bind active sites
with high aﬃnity. This was indeed the case for NAG-thiazoline
when serving as a reaction intermediate analogue of N-acet-
ylglucosaminidases [23]. NAG-thiazoline is derived directly
from GlcNAc, which is the repeating subunit of N-acetylglu-
cosaminidase’s homopolymeric substrate chitin, and the
inhibition constant of this inhibitor for the enzyme is four
orders of magnitude lower than that of its parent (compare
0.28 lM to 6 mM, respectively) [23]. The Kd value obtained for
NAG-thiazoline with sMltB was comparatively much higher,
but this needs to be considered in the context that the parent
compound GlcNAc does not bind the enzyme with any mea-
surable aﬃnity. Moreover, the situation of employing mono-
meric inhibitors to probe enzymes that act on branched- and/
or hetero-polymeric substrates appears to be more complex.
The example of the monosaccharide and transition-state in-
hibitor gluconolactone serves to illustrate this point well.
Notwithstanding its use and value over the past 40 years to
probe the mechanism of action of a variety of the hydrolytic
Fig. 7. Proposed reaction mechanism of MltB. Glu162 serves initially
as an acid to protonate the glycosidic linkage to be cleaved leading to
the formation of the muramoyl oxazolinium-ion intermediate, and
then as a base to abstract the C-6 hydroxyl proton promoting collapse
of the oxazolinium ion and concomitant formation of the 1,6-anhy-
dromuramoyl product.
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binds with Kd values in the mM range. As with the LTs, the
reaction center of lysozyme involves a muramoyl residue and
so like NAG-thiazoline, gluconolactone would represent a
very simple inhibitor. In fact, gluconolactone and other
monosaccharide-derived lactones, including that of GlcNAc,
proved to be too simple in structure for lysozyme as numerous
attempts by Phillips and co-workers to bind them into subsite
D at the catalytic center of lysozyme failed [42]. The lactone
was subsequently shown to be a transition state analogue of
the enzyme when it comprised a tetrasaccharide (viz. tetra-
GlcNAc), thereby permitting more extensive contacts with the
enzyme’s binding subsites [43].
In the light of these and other ﬁndings regarding carbo-
hydrases and simple transition-state analogues of their com-
plex substrates, it is not too surprising that NAG-thiazoline
was found to bind sMltB with relatively weak aﬃnity. This
view is consistent with our recent ﬁndings that the key features
of ligands associated with binding to sMltB include the D-
lactyl side chain and associated peptide at C-3 of muramoyl
residues [44]. Indeed, an extensive network of contacts is seen
in the crystal structure of E. coli Slt35-ligand complexes be-
tween the enzyme and both the D-lactyl moiety and the stem
peptide of the ligands [11]. At subsite )1, which is adjacent tothe site of cleavage, these include a hydrogen bond between the
invariant Arg188 residue and the carbonyl of the D-lactyl
group, and a salt bridge between the highly conserved Arg187
residue [5] and the free b-carboxyl group of the c-glutamyl
residue of the stem peptide. Recognizing that NAG-thiazoline
lacks both lactyl and peptidyl side chains in addition to being
only monomeric, thereby precluding important binding con-
tacts in subsites beyond the catalytic center of the enzyme,
eﬀorts have been directed towards the synthesis of thiazoline
derivatives that more closely mimic the muramyl substrate
with associated stem peptide. Unfortunately, success has not
been achieved to date due to the instability of the thiazoline
moiety associated with these derivatives during de-protection
reactions. Nonetheless, we are encouraged to continue this
research in the light of our recent observations that NAG-
thiazoline causes changes to both morphology and cell-surface
hydrophobicity of growing E. coli [31].
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